[an error occurred while processing this directive] | [an error occurred while processing this directive]
Efficacy and safety of high-dose versus conventional-dose conventionally fractionated external beam radiotherapy for stage T1b-4N0-1M0 prostate cancer:a meta-analysis
Wang Hui1,4, Xie Ruilin1,4, Qin Qingwei1,4, Li Na1,4, Wang Sheng1,4, Zhao Xue1,4, Qin Zhaohui2, Yao Yuanhu1,3
1Department of Radiation OncoloGy,The Affiliated Hospital of Xuzhou Medical University,Xuzhou 221002,China; 2School of Public Health,Xuzhou Medical University,Xuzhou 221004,China; 3School of Medical Imaging,Xuzhou Medical University,Xuzhou 221004,China; 4Graduate school of Xuzhou Medical University,Xuzhou 221004,China
AbstractObjective To systematically evaluate the clinical efficacy and safety between high-dose (74 to 80 Gy) and conventional-dose (64.0 to 70.2 Gy) conventionally fractionated external beam radiotherapy for stage T1b-4N0-1M0 prostate cancer in this meta-analysis. Methods A literature search was performed in PubMed,Embase,Cochrane Library,Web of Science,CBM,Wanfang Data,CNKI and Chongqing VIP to collect clinical trials on high-dose versus conventional-dose conventionally fractionated external beam radiotherapy of prostate cancer from the inception to July 1, 2018. The included literatures were evaluated by Cochrane quality evaluation criteria and subject to meta-analysis by using Review Manager 5.3 statistical software. Results A total of 7 randomized controlled clinical trials involving 4 132 patients were included in the meta-analysis. The meta-analysis showed that the high-dose and conventional-dose groups yielded similar 10-year overall survival (RR=1.01,95%CI:0.96 to 1.07,P=0.64) and 10-year prostate cancer-specific survival (RR=1.01,95%CI:0.98 to 1.03,P=0.47). The biochemical failure rate in the high-dose group was significantly lower than that in the conventional-dose group (RR=0.78,95%CI:0.70 to 0.86,P<0.01). Compared with the conventional-dose group,the incidence of late grade ≥2 gastrointestinal and genitourinary adverse reactions (RR=1.48,95%CI:1.31 to 1.67,P<0.01;RR=1.35,95%CI:1.06 to 1.73,P=0.02) was significantly higher in the high-dose group. Conclusion High-dose conventionally fractionated external beam radiotherapy has advantages in reducing the biochemical failure rate of patients with stage T1b-4N0-1M0 prostate cancer. Nevertheless, whether it can improve overall survival and prostate cancer-specific survival remains to be validated. High-dose radiotherapy also induce a higher incidence rate of late grade ≥2 gastrointestinal and genitourinary adverse reactions compared with conventional-dose radiotherapy.
Corresponding Authors:
Yao Yuanhu, Email:yyhxz@xzhmu.edu.cn
Cite this article:
Wang Hui,Xie Ruilin,Qin Qingwei et al. Efficacy and safety of high-dose versus conventional-dose conventionally fractionated external beam radiotherapy for stage T1b-4N0-1M0 prostate cancer:a meta-analysis[J]. Chinese Journal of Radiation Oncology, 2019, 28(7): 514-517.
Wang Hui,Xie Ruilin,Qin Qingwei et al. Efficacy and safety of high-dose versus conventional-dose conventionally fractionated external beam radiotherapy for stage T1b-4N0-1M0 prostate cancer:a meta-analysis[J]. Chinese Journal of Radiation Oncology, 2019, 28(7): 514-517.
[1]陈万青,郑荣寿,张思维,等.2013年中国恶性肿瘤发病和死亡分析[J]. 中国肿瘤,2017(1):1-7. DOI:10.11735/j.issn.1004-0242.2017.01. A001. Chen WQ,Zheng RS,Zhang SW,et al. Report of Cancer Incidence and Mortality in China,2013[J]. China Cancer,2017(1):1-7. DOI:10.11735/j.issn.1004-0242.2017.01. A001. [2]Iii MR, Hanks G, Thames H,et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer:Recommendations of the RTOG-ASTRO Phoenix Consensus Conference[J]. Int J Radiat Oncol Biol Phys,2006, 65(4):965-974. DOI:10.1016/j.ijrobp.2006.04.029. [3]Creak A,Hall E,Horwich A,et al. Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer:long-term follow-up[J]. Br J Cancer,2013,109(3):651-657. DOI:10.1038/bjc.2013.394. [4]Heemsbergen WD,Al-Mamgani A,Slot A,et al. Long-term results of the Dutch randomized prostate cancer trial:Impact of dose-escalation on local,biochemical,clinical failure,and survival[J]. RadiotherOncol,2014,110(1):104-109. DOI:10.1016/j.radonc.2013.09.026. [5]Kuban DA, Levy LB, Cheung MR,et al. Long-Term Failure Patterns and Survival in a Randomized Dose-Escalation Trial for Prostate Cancer. Who Dies of Disease?[J]. International journal of radiation oncology, biology, physics,2011,79(5):1310-1317. DOI:10.1016/j.ijrobp.2010.01.006. [6]Dearnaley DP,Jovic G,Syndikus I,et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer:long-term results from the MRC RT01 randomised controlled trial[J]. The Lancet Oncology,2014,15(4):464-473. DOI:10.1016/S1470-2045(14)70040-3. [7]Beckendorf V,Guerif S,Le Prise E,et al.70 Gy versus 80 Gy in localized prostate cancer:5-year results of GETUG 06 randomized trial[J]. Int J Radiat Oncol Biol Phys,2011,80(4):1056-1063. DOI:10.1016/j.ijrobp.2010.03.049. [8]Zietman AL,Bae K,Slater JD,et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate:long-term results from proton radiation oncoloGy group/american college of radioloGy 95-09[J]. J Clin Oncol,2010,28(7):1106-1111. DOI:10.1200/JCO.2009.25.8475. [9]Michalski JM,Moughan J,Purdy J,et al. Effect of standard vs. dose-escalated radiation therapy for patients with intermediate-risk prostate cancer:the NRG oncology RTOG 0126 randomized clinical trial[J]. JAMA Oncol,2018,4(6):e180039. DOI:10.1001/jamaoncol.2018.0039. [10]熊升远,阮同德. T3期前列腺癌治疗进展[J]. 国际泌尿系统杂志,2015,2):279-283. DOI:10.3760/cma.j.issn.1673-4416.2015.02.038. Xiong SY,Ruan TD. Progress in the treatment of stage T3 prostate cancer[J]. Int J Urol Nephrol,2015,2):279-283. DOI:10.3760/cma.j.issn.1673-4416.2015.02.038. [11]Koupparis AJ,Grummet JP,Hurtado-Coll A,et al. Radical prostatectomy for high-risk clinically localized prostate cancer:a prospective single institution series[J]. Can Urol Assoc J,2011,5(6):E156-161. DOI:10.5489/cuaj.10057. [12]Vora SA,Wong WW,Schild SE,et al. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer[J]. Int J Radiat Oncol Biol Phys,2007,68(4):1053-1058. DOI:10.1016/j.ijrobp.2007.01.043. [13]Someya M,Hori M,Tateoka K,et al. Results and DVH analysis of late rectal bleeding in patients treated with 3D-CRT or IMRT for localized prostate cancer[J]. J Radiat Res,2015,56(1):122-127. DOI:10.1093/jrr/rru080. [14]Kuban DA,Tucker SL,Dong L,et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer[J]. Int J Radiat Oncol Biol Phys,2008,70(1):67-74. DOI:10.1016/j.ijrobp.2007.06.054.
2019, Vol. 28 
